Marea Therapeutics Strengthens Leadership with New Appointments
Marea Therapeutics, Inc., a clinical-stage biotechnology company focused on innovative solutions for cardiometabolic diseases, is making significant strides in its journey. The company has recently expanded its management team and its board of directors, welcoming new experts who will play crucial roles in advancing its mission to develop state-of-the-art therapeutics.
Building Momentum in Clinical Development
Josh Lehrer, M.D., M.Phil., FACC, the CEO of Marea Therapeutics, expressed his enthusiasm about the company's progress. He stated, "Momentum continues to build at Marea as we advance our lead program, MAR001, through clinical development." This program is pivotal for Marea, aiming at addressing serious metabolic dysfunctions that pose risks for cardiovascular diseases.
Introducing New Leadership
As part of this growth, Marea Therapeutics welcomes Rebecca Juliano, Ph.D., who has been appointed as the Chief Development Officer. Dr. Juliano brings an impressive 25-year background in lipid-related research and has held prominent roles in the industry. Her experience in clinical program design and execution will be invaluable as Marea transitions to the next phase of its growth.
Before taking her role at Marea, Dr. Juliano served as the COO of a biotech startup where she developed key clinical strategies for cardiovascular and rare disease treatments. Her leadership at Amarin Pharma led to the successful execution of the cardiovascular outcomes trial, REDUCE-IT, which garnered several international approvals and accolades, shaping clinical guidelines worldwide.
A Vision for Corporate Development
Joining Dr. Juliano is Max Zeiberg, who has been appointed as Senior Vice President of Corporate Development. With extensive experience in business development from his tenure at Sana Biotechnology and Graphite Bio, Mr. Zeiberg has a proven track record in strategic planning and partnerships. His history at Gilead Sciences, where he directed virology partnering and M&A activities, showcases his ability to drive growth through strategic alignment.
His educational background includes a B.S. in biomedical engineering from Columbia University and an MBA from Northwestern University's Kellogg School of Management, aligning with Marea's commitment to marrying scientific excellence with business acumen.
New Insights on the Board
Additionally, Robert A. Harrington, M.D., has been appointed to Marea's board of directors. A distinguished cardiologist, Dr. Harrington serves as the Dean of Weill Cornell Medicine and is a leader in clinical research concerning antithrombotic therapies. His rich experience includes roles at Yale University and the Duke Clinical Research Institute, bringing valuable insights to Marea's strategic vision for innovative therapies.
Dr. Harrington’s academic credentials are impressive; he holds a Bachelor’s degree in English from the College of the Holy Cross and an M.D. from Tufts University School of Medicine. His leadership will complement Marea's scientific endeavors as it strives to improve methodologies in clinical research.
About Marea Therapeutics
Marea Therapeutics specializes in developing groundbreaking solutions for cardiometabolic diseases through cutting-edge human genetics. The company's flagship program, MAR001, is currently in clinical development, targeting adults facing metabolic challenges. This ambitious initiative underscores Marea's commitment to pioneering first-in-class medications while being backed by a knowledgeable leadership team steeped in experience across relevant scientific domains.
For those interested in following the company’s advancements in research and clinical development, Marea invites you to explore their website and stay updated on their latest news through social media channels.
Frequently Asked Questions
What is Marea Therapeutics focused on?
Marea Therapeutics is focused on developing innovative treatments for cardiometabolic diseases using advanced genetic technologies.
Who are the new leaders at Marea Therapeutics?
Rebecca Juliano, Ph.D., has been appointed as Chief Development Officer, and Max Zeiberg is now the Senior Vice President of Corporate Development. Robert A. Harrington, M.D., joins the board of directors.
What is the lead program at Marea Therapeutics?
The lead program at Marea is MAR001, which is in Phase 2 clinical development aimed at addressing metabolic dysfunctions in adults at risk for cardiovascular diseases.
What experience does Rebecca Juliano bring to Marea?
Dr. Juliano has over 25 years of experience in lipid-related research and has previously led significant clinical trials at major biopharma companies.
How can I learn more about Marea Therapeutics?
You can visit Marea Therapeutics' official website and follow their social media platforms for updates and insights into their research and developments.
